Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 15/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LIPC | P11150 | 13/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464300 | 0.91 | LIPG (0.52) | LIPGNPC1RAB9ASMN1; SMN2LIPC | |
| SCHEMBL15470710 | 0.85 | LIPG (0.51) | LIPGLIPCTRPV1 | |
| SCHEMBL15558628 | 0.82 | MAPT (0.48) | LIPGNPC1RAB9ASMN1; SMN2LIPC | |
| SCHEMBL15464108 | 0.79 | LIPG (0.55) | LIPGNPC1RAB9ALIPC | |
| SCHEMBL15464709 | 0.78 | LIPG (0.67) | LIPGLIPC | |
| SCHEMBL15470697 | 0.77 | LIPC (0.53) | LIPGNPC1RAB9ASMN1; SMN2LIPC | |
| SCHEMBL22371439 | 0.76 | SMN1; SMN2 (0.62) | LIPGNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL15464393 | 0.76 | LIPC (0.74) | LIPGLIPC | |
| SCHEMBL9443177 | 0.74 | SMN1; SMN2 (0.59) | LIPGNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL9443174 | 0.74 | SMN1; SMN2 (0.59) | LIPGNPC1RAB9ASMN1; SMN2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875007-B1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8987314-B2 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LIPE, CEL | LIPG 1/4885NPC1 1652/4885RAB9A 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.